He discusses the Biogen deal, and how it is a sign of increased activity Alloy sees in their genetic medicines business. Plus, monoclonals vs multispecifics, and the state of discovery work today.

He described the discovery work that Alloy does with its client partners, and highlighted emerging areas of science. Plus, the importance...

He describes his career path and learnings from the tech industry, co-founding Adimab, the work that Alloy and 82VS do to support and...